This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Medical Ethics  • Neurology  • Alzheimer Disease  • Cognitive Disorders  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Drs Johnson and Lassere emphasize the importance of prespecified analyses in the reporting and interpretation of randomized clinical trials. The protocol for a trial serves as the centerpiece, and its analysis plan needs to specify not only the type and method of analysis but the efficacy and safety outcomes as well. Information about amendments, their timing, and the rationales should become part of the protocol. Ideally, this full protocol should be available to reviewers and editors when the manuscript for the corresponding trial is submitted to a journal. As Johnson and Lassere point out, the FDA Amendments Act requirement to post "the full protocol or such information on the protocol for the trial as may be necessary to help to evaluate the results of the trial"¹ may prove especially useful.

The original protocols and any subsequent amendments for the rofecoxib trials in patients with Alzheimer disease or cognitive . . . [Full Text of this Article]

Bruce M. Psaty, MD, PhD
psaty@u.washington.edu

Richard A. Kronmal, PhD
University of Washington
Seattle

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():900-900.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():900-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():901-901.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
, , and
JAMA. ;300():901-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():902-902.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():902-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies

JAMA. ;300():903-903.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():903-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
and
JAMA. ;300():904-904.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
, , and
JAMA. ;300():904-905.
FULL TEXT  

Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies--Reply
and
JAMA. ;300():905-906.
FULL TEXT